Related Experiment Video

Updated: May 26, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Prostate cancer in 2011: Hitting old targets better and identifying new targets

Yu Chen1, Howard I Scher

  • 1Human Oncology and Pathogenesis Program and Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

Nature Reviews. Clinical Oncology
|January 11, 2012
PubMed

Insights

New treatments for advanced prostate cancer extended survival in 2011. This progress occurred alongside debate regarding prostate-specific antigen (PSA) screening recommendations.

Area of Science:

  • Oncology
  • Urology
  • Medical Oncology

Background:

  • Late-stage castration-resistant prostate cancer (CRPC) presents significant treatment challenges.
  • The year 2011 saw advancements in therapeutic options for CRPC.

Observation:

  • Three novel agents demonstrated improved overall survival in CRPC patients.
  • A fourth agent effectively mitigated skeletal-related events, reducing morbidity.
  • These therapeutic gains occurred amidst controversy surrounding prostate-specific antigen (PSA) screening guidelines.

Findings:

  • Multiple treatment modalities now exist for advanced prostate cancer, offering prolonged survival.
  • Significant reduction in skeletal metastasis complications was achieved.
  • Controversy surrounding PSA screening recommendations impacted early detection discussions.

Implications:

  • The expanding armamentarium for CRPC offers improved patient outcomes.
  • Management of skeletal-related events is crucial for quality of life in advanced prostate cancer.
  • Ongoing debate regarding PSA screening necessitates careful consideration of diagnostic strategies.

More Related Videos

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization07:34

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...